Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Abstract

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

1 . (canceled) 
     
     
         2 . The pharmaceutical composition of  claim 7 , where the crystalline hydrochloride salt is characterized by having one or more additional diffraction peaks at 2θ values selected from 8.11±0.20, 13.18±0.20, 16.06±0.20, 18.38±0.20, 23.76±0.20, 26.32±0.20, 27.24±0.20, 29.60±0.20, and 31.94±0.20. 
     
     
         3 . The pharmaceutical composition of  claim 7 , where the crystalline hydrochloride salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in  FIG. 1 . 
     
     
         4 . The pharmaceutical composition of  claim 7 , where the crystalline hydrochloride salt is characterized by a differential scanning calorimetry trace which has a melting point of about 196.9° C. 
     
     
         5 . The pharmaceutical composition of  claim 7 , where the crystalline hydrochloride salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in  FIG. 2 . 
     
     
         6 . (canceled) 
     
     
         7 . The pharmaceutical composition comprising a pharmaceutically acceptable carrier, crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]-piperidine, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.20, 10.22±0.20, 17.16±0.20, and 21.78±0.20, and a secondary therapeutic agent selected from anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof. 
     
     
         8 - 17 . (canceled)